Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SBFM BUY Rating Target Price Increased to $3/share........
Sunshine Biopharma Inc.
Rating: Buy
Sunshine Biopharma Beats Our Revenue
Expectations - Raising Our Target Price to $3.
Full Report: https://sunshinebiopharma.com/assets/analysts%20reports/20230814%20-%20Sunshine%20Biopharma%20Reports%20Q2-2023.pdf?_t=1693248489
I think AXXA could be between $.50-1.00 in 2024 and I'm sticking with this prediction for now!
From today's low price it appears that nobody expects that to happen or that SBFM has any positive updates on their Cancer and Covid research projects! You would think they would have made some progress in the past 6-12 months.
Yes, we need some NORA sunshine soon!
Are you GIDDY about AXXA going UP soon? GIDDYUP!
What will happen to Nora Pharma when the Titanic sinks?
So are you saying this is for a Merger/Acquisition and not a R/S vote?
Is this more bad news for SBFM (see link)? Seems to be a precurser to a R/S vote? All opinions welcomed!
https://ih.advfn.com/stock-market/NASDAQ/sunshine-biopharma-SBFM/stock-news/91901043/form-pre-14a-other-preliminary-proxy-statements
And per the Q reports, the Float has stayed the same which was the only good news thus far!
Float: 593,902,574 as of June 30, 2023.
Even if the recent Q reports aren't complete at least they give this board something to talk and speculate about instead of silence!
Yes, still a lot of unanswered questions. The only thing new are the filed reports even though they are missing the financial info. I assume we will see Amended reports soon. My assumption is they finally filed both Q reports to get current again, but need to amend/complete the reports. We'll see how this all pans out in the coming days/weeks/months. I'm not expecting to know the reality until 2024, whether good or bad!
I see some new filings on OTC Markets. Looks like CCAJ is getting closer to Current again.
Let's just keep AXXA going up 10%+ per day and we'll all be fine!
Thanks. We need some answers even if not directly from the company!
Thanks for the queries and let us know if you do get anymore info. I also noted Jaybee is back saying he can help fix CCAJ. We shall see!
Each graph is different and the CCAJ graph is exactly what we saw happen since 2019!
All I'm saying is somehow CCAJ got in the TOP 6 for this publication.
CCAJ listed as one of the TOP 6 stocks under $.01 in this WEALTH DAILY article on August 17, 2023. Not sure what to make of this, but seems interesting to be on this list. Perhaps something is in the works after all!
https://www.wealthdaily.com/penny-stocks-under-1-cent/
Good start today (+27%). We'll see where AXXA goes in the coming days/weeks!
Sounds good. Let's see if AXXA can get to $.20 by the end of 2024, after running through $.02 in early 2024!
How about an all-time high in 2024? That is not too long to wait for the ultra patient shareholder.
Well, AXXA has dropped from $.08 starting in January 2022 so it is time for it to travel back to $.08 starting in January 2024 if not sooner. As you know, some on this board think it should be $5-10. I think anything over $.02 is a good start then back to $.08 by the end of 2024.
I'll be very surprised if AXXA ever gets to $1 let alone $5.
How about a new 52 week high ($.02+) in early 2024! Very possible with the year over year growth in revenue and assets.
I know there is a lot of negativity here and for good reason, but don't forget the recent SBFM BUY rating. I know the below rating is from Aegis, but a rating nonetheless! Target date for $2.60 is August 2024.
"In the last 3 months, 1 ranked analysts set 12-month price targets for SBFM. The average price target among the analysts is $2.60. Analysts compare their price target to the current market price of the stock to determine how much potential upside or downside movement there could be in the stock price."
If so, Pitre should put an "OUT OF BUSINESS" sign on the website....or a FOR SALE sign!
https://coastalcapitalacquisitioncorp.com/
He was touted as a CEO who could get things done, but something happened in late '22 that says otherwise.
Hi CoastalCapitalAcquisitionCorp-CCAJ,
Why haven't you filed the last Q1 2023 report (due May 15, 2023)?
Why have you been silent since May 15, 2023?
Why haven't you updated Shareholders about whose in control of CCAJ?
Why haven't you updated Shareholders on the status of 3 acquisition candidates?
What haven't you updated Shareholders on the status of any construction projects?
The silence is making Shareholders think management has abandoned CCAJ. What is happening behind the silence?
We'll see what happens with NAS in September and then I'll probably still be holding into 2024 to see what happens with Nora Pharma (?R/M) and with UoA based on this:
"In addition, the Company and the University of Arizona entered into an Option Agreement whereby the Company was granted a first option to negotiate a royalty-bearing commercial license for the underlying technology of the Research Project. Encouraged by the results obtained to date, we submitted a Notice of Option Exercise to the University of Arizona on September 13, 2022."
Also got this to see what happens in 2024: "In February 2023, we signed a research agreement with the Jewish General Hospital (“JGH”), to complete the IND-enabling studies. The JGH has also agreed to negotiate with us the terms for Phase I Clinical Trials. Adva-27a’s initial indication will be pancreatic cancer for which there are currently little or no treatment options available. All aspects of the clinical trials in Canada will employ FDA standards at all levels."
Also got this to see what happens in 2024: "We recently concluded an agreement with a specialized partner for the purposes of formulating our K1.1 mRNA molecules into lipid nanoparticles, ready for use to conduct studies in xenograft mice. We anticipate commencing such studies within approximately the next twelve months."
Thanks. I've been wondering about a R/M and it makes sense to have the company bringing in $22M/year become the parent company. Perhaps the CEO of NoraPharma could also advance the proprietary efforts more quickly. I know it is slow with the FDA, but seems like the initial IND application approval could happen by 2024. That is the next step SBFM has been talking about so let's see if Nora can actually make that happen!
Thanks for the thorough summary of all the issues with SBFM! On a good note, their subsid NoraPharma generated quarterly revenue of $5.5M and are expected to continue quarterly growth. Annually that would be about $22M which if memory serves me correctly NoraPharma was at $15M/year when purchased by SBFM.
Needless to say SBFM has a lot of hurdles to overcome so we'll see what happens in the coming days/weeks/months/years.
PS: Aegis thinks they are worth $2.60/share so we'll see about that too!
$2.60 per Aegis BUY Rating on 8/7/23........
Aegis Capital Initiates Sunshine Biopharma at Buy Rating With $2.60
12:21 PM ET 8/7/23 | MT Newswires
--Aegis Capital Initiates Sunshine Biopharma at Buy Rating With $2.60
12:21 PM EDT, 08/07/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
Well, maybe one day they will take a Twitter Tweeter class and improve the odds of their tweets moving the share price up instead of down or flat! Just something to ponder until 2024!
Anyone disputing below description of AXXA...Who we are? If so, please provide your point by point factual dispute of below description.
Exxe Group, Inc. is a publicly traded FinTech company. Our Common shares trade under the ticker symbol: AXXA. The Company is a U.S. corporation organized under the laws of the State of Delaware.
Exxe Group operates at the nexus of Private Equity, Venture Capital, and Distressed Debt. The Company seeks to acquire controlling equity interests in undervalued assets. Once an asset is acquired, Exxe takes an active role by providing both capital and structured financing, as well as operational management expertise.
Since 2018 Exxe Group has successfully executed 28 acquisitions across several industries.
Exxe has four operating segments: Real Estate, FinTech, Digital & Diversified Technologies, and Agribusiness. Exxe’s diversified asset base includes majority controlling interests in multiple entities across a wide range of industries and countries, as well as minority interests in selected startups.
Real Estate has a diversified collection of commercial real estate assets including hotels, mortgages, rental properties, and undeveloped land located in Germany, Switzerland, Eastern Europe, and the United States and Canada.
FinTech includes Blockchain, e-Commerce platforms, Cryptocurrency Exchange and fiat Foreign Exchange (Forex) platforms, and Venture Capital. The Venture Capital assets include a range of early-stage potentially disruptive, high growth assets. These assets are generally illiquid, generate little to no current revenue, and the assets may undergo internal restructurings to establish fresh base valuations. Holdings in this class also have the potential to grow their assets and revenues with well above-average returns.
Digital & Diversified Technologies includes a diversified range of software and hardware assets. Software assets include, but are not limited to, Artificial Intelligence (AI), digital community assets, and media assets. Hardware assets include, but are not limited to, auto parts manufacturing equipment, car engine repair tooling, robotics, and waterway dredging machinery.
Agribusiness assets span a range of activities centered around farming, storage and transportation. These investments allow the Company to finance growing crops such as barley, wheat, corn, sunflower seeds, and hemp in fields and shipping those crops to wholesale markets around the world. This includes financing, trading, processing, storage, testing, and logistics.
Yes, but..................do all startups borrow $63M and then have the PPS tank 5 years later? We're seeing the tank in 2023 and I'm wondering why. The only 4 explanations I've seen thus far (on this board) are:
1. Accumulated debt and CDers
2. Russian Laundering Scam
3. Fake companies
4. AXXA has disgruntled ex-employees and enemies
Do you have an explanation not captured above?
Thanks
No matter what enemies AXXA has, the naysayers on this board are right about a couple things: AXXA has borrowed a lot of money over the years and the PPS is very low. Perhaps these 2 aspects are correlated, and perhaps there is something else going on that is pulling the price down.
As I've said before, time is the great truth seeker and 2024 may be the year of truth for AXXA whether good or bad! Until then I'm Neutralish on this stock.
I saw reference to AXXA as a "Russian laundering scam" today and have seen many references to Russian this or that over the past several months. I suppose the SEC might want to look into that? If this is true, then we've all been had....if false then I think that is what is called slander! Either way it would be nice to know the facts on that. Time will tell as it is the great truth seeker!
Looking forward to 2024! 2023 has been a downer so let's see if 2024 is an upper!
Don't you believe in miracles? I believe 2024 will be the miracle year for debt reduction, higher revenue, spin-offs, audits and thus a much higher PPS. But as you know, believing in a miracle doesn't mean it will happen. Someone has to do the work. Perhaps that will be the poster who has expressed interest in buying AXXA, and that would be a miracle!
PS: I do like your posts reminding us of the current reality.
AXXA needs to pay off the debt to fix this problem. What an idea! If you can do that we welcome you as the new owner and CEO.
Now just need some volume to buy up the unrestricted shares (619,687,152) and move the price back up. 5M/day x 120 days would do the trick!
Most of the O/S are RESTRICTED....Game On....
FROM OTCMARKETS:
Outstanding Shares: 3,399,739,050
Restricted: 2,780,051,898
Unrestricted: 619,687,152
Exciting times this week. New lows for 2023. Should make for an exciting 2024 when it hits new highs (assuming this turns out NOT to be a SSS (Share Selling Scam)!